EUVIMEDEUVIMED entdecken
Crossref

Hepatocellular Carcinoma and Chemotherapy: The Role of p53

A F Brito, A M Abrantes, C Pinto-Costa, A R Gomes, A C Mamede, J Casalta-Lopes, A C Gonçalves, A B Sarmento-Ribeiro, J G Tralhão, M F Botelho

Chemotherapy · 2012 · 58 (5) · 381-386

DOI: 10.1159/000343656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 21.12.2012. Verfasst von A F Brito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biophysics Unit, IBILI - Faculty of Medicine, University of Coimbra, Coimbra, Portugal. anabrito816@gmail.com. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is the most common primary neoplasm of the liver. A major proportion of HCCs also present mutation of the gene that encodes p53, which confers chemoresistance. The main goal of this work is to investigate the effect of cisplatin, doxorubicin and 5-fluoruracil (5-FU) in three human HCC cell lines which differ in p53 expression.

Methods

HepG2 (expressing normal p53), HuH7 (expressing mutated p53) and Hep3B2.1-7 (not expressing p53) cell lines were cultivated in the presence of cisplatin, doxorubicin and 5-FU. Cell proliferation was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT assay). The type of cell death and Bax and Bcl2 activation were assessed by flow cytometry.

Results

It was found that for all of the cell lines studied, the agent that gave the most satisfactory results was doxorubicin. 5-FU demonstrated no activity in these cell lines.

Conclusions

For all the cell lines studied, doxorubicin was the most satisfactory agent. In HepG2 and HuH7 cell lines, it can activate Bax with statistical significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsApoptosisCarcinoma, HepatocellularCell Line, TumorCisplatinDoxorubicinFluorouracilHep G2 CellsHumansLiver NeoplasmsProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53bcl-2-Associated X Protein

Substanzen

Antineoplastic AgentsProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53bcl-2-Associated X ProteinDoxorubicinCisplatinFluorouracil

Autor:innen und Institutionen

  • Biophysics Unit, IBILI - Faculty of Medicine, University of Coimbra, Coimbra, Portugal. anabrito816@gmail.com

Zitieren

APA

Brito, A. F., Abrantes, A. M., Pinto-Costa, C., Gomes, A. R., Mamede, A. C., Casalta-Lopes, J., Gonçalves, A. C., Sarmento-Ribeiro, A. B., Tralhão, J. G., & Botelho, M. F. (2012). Hepatocellular Carcinoma and Chemotherapy: The Role of p53. Chemotherapy, 58(5), 381-386. https://doi.org/10.1159/000343656

Vancouver

Brito AF, Abrantes AM, Pinto-Costa C, Gomes AR, Mamede AC, Casalta-Lopes J, et al. Hepatocellular Carcinoma and Chemotherapy: The Role of p53. Chemotherapy. 2012;58(5):381-386. doi:10.1159/000343656

BibTeX
@article{Brito2012,
  author = {Brito, A F and Abrantes, A M and Pinto-Costa, C and Gomes, A R and Mamede, A C and Casalta-Lopes, J and Gonçalves, A C and Sarmento-Ribeiro, A B and Tralhão, J G and Botelho, M F},
  title = {Hepatocellular Carcinoma and Chemotherapy: The Role of p53},
  journal = {Chemotherapy},
  year = {2012},
  volume = {58},
  number = {5},
  pages = {381--386},
  doi = {10.1159/000343656}
}
Kostenlos starten →